Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Boyko

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2019
Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk groupAlexey Boyko
BMC Neurology|March 11, 2018
Pediatric multiple sclerosis: a reviewRaed Alroughani, Alexey Boyko
Brain Sciences|May 24, 2020
Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of StudiesAlexey Boyko, Mikhail Melnikov
Journal of the Neurological Sciences|January 29, 2010
Recent advances in multiple sclerosis: challenging paradigmsAlexey Boyko, Alberto Alain Gabbai
International Journal of Molecular Sciences|June 2, 2021
Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?Mikhail Melnikov, Mikhail Pashenkov, Alexey Boyko
Neuroimmunomodulation|October 7, 2016
The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple SclerosisAlexey Boyko, Mikhail Melnikov, Rustam Zhetishev, et al.
Multiple Sclerosis and Related Disorders|February 18, 2018
The influence of biogenic amines on Th17-mediated immune response in multiple sclerosisMikhail Melnikov, Vladimir Rogovskii, Alexey Boyko, et al.
Pharmacogenetics and Genomics|December 19, 2015
Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugsEkaterina Tsareva, Olga Kulakova, Alexey Boyko, et al.
Annals of Neurology|May 21, 2013
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosisOmar Khan, Peter Rieckmann, Alexey Boyko, et al.
Gene|July 21, 2020
Mitonuclear interactions influence multiple sclerosis riskMaxim Kozin, Olga Kulakova, Ivan Kiselev, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2019
Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk groupAlexey Boyko
BMC Neurology|March 11, 2018
Pediatric multiple sclerosis: a reviewRaed Alroughani, Alexey Boyko
Brain Sciences|May 24, 2020
Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of StudiesAlexey Boyko, Mikhail Melnikov
Journal of the Neurological Sciences|January 29, 2010
Recent advances in multiple sclerosis: challenging paradigmsAlexey Boyko, Alberto Alain Gabbai
International Journal of Molecular Sciences|June 2, 2021
Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?Mikhail Melnikov, Mikhail Pashenkov, Alexey Boyko
Neuroimmunomodulation|October 7, 2016
The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple SclerosisAlexey Boyko, Mikhail Melnikov, Rustam Zhetishev, et al.
Multiple Sclerosis and Related Disorders|February 18, 2018
The influence of biogenic amines on Th17-mediated immune response in multiple sclerosisMikhail Melnikov, Vladimir Rogovskii, Alexey Boyko, et al.
Pharmacogenetics and Genomics|December 19, 2015
Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugsEkaterina Tsareva, Olga Kulakova, Alexey Boyko, et al.
Annals of Neurology|May 21, 2013
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosisOmar Khan, Peter Rieckmann, Alexey Boyko, et al.
Gene|July 21, 2020
Mitonuclear interactions influence multiple sclerosis riskMaxim Kozin, Olga Kulakova, Ivan Kiselev, et al.
Pageof 7